Trial
NCT00638378
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
Prostate Cancer
Intervention
Ruxolitinib
Why stopped
According to the protocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-12